Abstract 1066
Background
Ostomy patients (pts) can develop some complications treated by nurse enterostomista, such as skin alterations and early or late complications. Stomal complications have a varying incidence (from 25 to 35%). Neoplastic ostomy pts often undergo chemo (CT) and/or radiation therapy (RT), also in association, and they can show stomal lesions or complications with an important impact on their daily life. Stomal side effects induced by CT-RT represent an important problem for pts, who need for a competent and organized support in order to be able to cope with them. In the literature, few studies report the care and assistance to the stomized pts.The aim of this study was to detect precociously stomal complications in order to treat them early, improving pts quality of life, and to demonstrate that these complications are more frequent in pts treated with CT and/or RT.
Methods
From 11.2017 to 5.2018 60 cancer ostomy pts were surgically treated for different types of cancers at our institution. 29 out 60 have been also treated with CT and/or RT at Medical Oncology Dept. 73% were male and 27% female. We evaluated stomal complications and classified them according to SACS scale. Our aim was to demonstrate a higher percentage of stomal complications in pts CT and/or RT treated vs untreated pts.
Results
At a median follow-up of 4 months, 29 out 60 ostomy pts were treated with CT, 2 with CT-RT, the remaining 29 underwent follow-up. 15 out 29 pts (51%) treated with CT and/or RT showed stomal complications: 14 with SACS - L1 skin alterations (redness without loss of substance) and 1 with SACS-L2 lesion (with loss of substance). Patients undergoing follow-up didn’t have any stomal complications.
Conclusions
Despite the recognized limitations of our study (small sample size and short median follow-up) we can conclude that there is an increase of complications in ostomy pts treated with CT and/or RT vs untreated pts and that this problem occurs in over half of population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cristoforo Ferrero.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2607 - Single cycle induction treatment with Cisplatin/Docetaxel plus Durvalumab/Tremelimumab in Stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial)
Presenter: Markus Hecht
Session: Poster Display session 3
Resources:
Abstract
1388 - Radiotherapy plus cisplatin (CDDP) or cetuximab (C225) in human papilloma-virus (HPV)-associated oropharyngeal cancer (OPC)? A dillema finally resolved. An updated meta-analysis.
Presenter: Petar Suton
Session: Poster Display session 3
Resources:
Abstract
1478 - Treatment outcomes of head and neck cancer patients 70 years and older receiving different chemo-radiation combinations.
Presenter: Majd Issa
Session: Poster Display session 3
Resources:
Abstract
3985 - Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs
Presenter: Jovian Yu
Session: Poster Display session 3
Resources:
Abstract
4036 - Final results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: study PANTERA
Presenter: Javier Martinez Trufero
Session: Poster Display session 3
Resources:
Abstract
4779 - Window of Opportunity for Durvalumab (MEDI4736) plus Metformin Trial in Squamous Cell Carcinoma of the Head and Neck (SCCHN): interim safety analysis
Presenter: Tony Richa
Session: Poster Display session 3
Resources:
Abstract
2757 - Severe Oral Mucositis (SOM) Mitigation by Genetically Modified Lactococcus Lactis Bacteria (LLB) Producing Human Trefoil Factor 1 (hTFF1; AG013) in Patients Being Treated With Concomitant Chemoradiation (CRT) for Oral and Oropharyngeal Cancers (OCOPC)
Presenter: Suraj Singh
Session: Poster Display session 3
Resources:
Abstract
5559 - Transcriptome signatures of treatment responses in a preoperative window of opportunity trial of nivolumab and tadalafil in resectable squamous cell carcinoma of the head and neck
Presenter: Sanket Shukla
Session: Poster Display session 3
Resources:
Abstract
3263 - Risk and Impact of Renal Impairment of Locally Advanced Head and Neck Squamous Cell Carcinoma Patients Who Received Chemoradiotherapy with Cisplatin
Presenter: Thana Patimarattananan
Session: Poster Display session 3
Resources:
Abstract
3128 - Systemic bevacizumab for the treatment of recurrent respiratory papillomatosis: A retrospective analysis from an academic tertiary care center
Presenter: Sumita Trivedi
Session: Poster Display session 3
Resources:
Abstract